-
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.Lee CW, Ahn JM, Park SJ et al. -
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial SubanalysisJurrienM Berg, A de Veer, the RE-DUAL PCI Steering Committee and Investigators et al.
-
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trialFeres F, Costa RA, OPTIMIZE Trial Investigators.
-
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-AnalysisM Valgimigli , R Mehran, SIDNEY Collaboration et al.
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary InterventionD Sibbing, D Aradi, D Alexopoulos et al.
-
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS TrialSS Anand, JW Eikelboom, COMPASS Trial Investigators.
-
Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)Orme RC, Parker WAE, Storey RF et al.
-
Genotyping to Guide Clopidogrel Treatment: An In-Depth Analysis of the TAILOR-PCI TrialNaveen L. Pereira, MBBS, FACC
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
